AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today that it has entered into an agreement with Slater Endoscopy, LLC to distribute the cold Ensizor® Flexible Endoscopic Scissors in the United States, Europe, and select other markets.
The Ensizor Flexible Endoscopic Scissor is indicated to cut and dissect tissue and sutures during endoscopic procedures. The innovative Edge Flex™ technology greatly enhances the cutting performance of endoscopic scissors by offering a very thin, yet rigid blade construction. The rigid armature provides unparalleled strength while the flexible blades ensure constant cutting contact providing physicians reliable and consistent cutting performance.
“The Ensizor scissors are complementary to OverStitch™ endoscopic suturing procedures. As the OverStitch user base expands and as physicians explore more uses for suturing, it is important for us to meet the need for cutting and removal of sutures,” said Todd Newton, CEO of Apollo Endosurgery. “We have been very impressed by the Ensizor technology and our customer base will find Ensizor to add value for their therapeutic endoscopic needs.”
“We are excited to work with Apollo Endosurgery, in order to bring the Ensizor scissors to broader adoption in the growing area of therapeutic endoscopy,” said Charlie Slater, CEO of Slater Endoscopy.
The Ensizor Flexible Endoscopic Scissors are available for sale immediately through Apollo in the United States and select European countries.
About OverStitch™
The OverStitch endoscopic suturing system enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures from a flexible endoscope. This new technology enables a secure approximation of tissue endoscopically and a wide range of less invasive solutions for physicians who treat defects in both the upper and lower GI tract of their patients. Additionally, physicians are leveraging endoscopic suturing to perform a variety of advanced bariatric procedures. For more information regarding OverStitch go to: www.apolloendo.com.
About Slater Endoscopy, LLC.
Slater Endoscopy leverages its engineering strength and sales organization to serve customers in the United States and distribution partners world-wide. The company was founded in 2012 and is rapidly developing an innovative product portfolio.
Slater Endoscopy’s headquarters and manufacturing facility are located in Miami, Florida. To learn more, visit www.slaterendoscopy.com.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies for the treatment of obesity, a condition facing over 650 million people globally, as well as other gastrointestinal conditions. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the ORBERA® Intragastric Balloon, and the LAP-BAND® Adjustable Gastric Banding System.
Apollo’s common stock is traded on Nasdaq Global Market under the symbol "APEN." For more information regarding Apollo, go to: www.apolloendo.com.
© 2018 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: reports of adverse events related to our products, developments in medical technology, regulatory approvals and extensive regulatory oversight by the FDA or other regulatory bodies, unfavorable media coverage related to our products or related procedures, reimbursement decisions by private or government payors, physician adoption and recommendations of procedures utilizing our products and other factors detailed from time to time in the reports Apollo files with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2017, and its Form 10-Q for the three months ended June 30, 2018 and its FORM 424B5 Prospectus filed June 21, 2018. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
